FDA Approved: KESIMPTA — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Kesimpta (ofatumumab) from Novartis Pharmaceuticals Corporation, expanding its label/indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

SUPPL AP for KESIMPTA (OFATUMUMAB)